ID   RON_HUMAN               Reviewed;        1400 AA.
AC   Q04912; B5A944; B5A945; B5A946; B5A947;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   20-APR-2010, sequence version 2.
DT   10-MAY-2017, entry version 184.
DE   RecName: Full=Macrophage-stimulating protein receptor;
DE            Short=MSP receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=CDw136;
DE   AltName: Full=Protein-tyrosine kinase 8;
DE   AltName: Full=p185-Ron;
DE   AltName: CD_antigen=CD136;
DE   Contains:
DE     RecName: Full=Macrophage-stimulating protein receptor alpha chain;
DE   Contains:
DE     RecName: Full=Macrophage-stimulating protein receptor beta chain;
DE   Flags: Precursor;
GN   Name=MST1R; Synonyms=PTK8, RON;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM RON), AND VARIANTS GLN-322;
RP   ARG-523 AND GLY-1195.
RC   TISSUE=Keratinocyte;
RX   PubMed=8386824;
RA   Ronsin C., Muscatelli F., Mattei M.-G., Breathnach R.;
RT   "A novel putative receptor protein tyrosine kinase of the met
RT   family.";
RL   Oncogene 8:1195-1202(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RX   PubMed=8816464; DOI=10.1128/MCB.16.10.5518;
RA   Collesi C., Santoro M.M., Gaudino G., Comoglio P.M.;
RT   "A splicing variant of the RON transcript induces constitutive
RT   tyrosine kinase activity and an invasive phenotype.";
RL   Mol. Cell. Biol. 16:5518-5526(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS RON-1; RON-2; RON-3 AND RON-4).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   INTERACTION WITH PIK3R1.
RX   PubMed=7687741; DOI=10.1128/MCB.13.8.4600;
RA   Ponzetto C., Bardelli A., Maina F., Longati P., Panayotou G.,
RA   Dhand R., Waterfield M.D., Comoglio P.M.;
RT   "A novel recognition motif for phosphatidylinositol 3-kinase binding
RT   mediates its association with the hepatocyte growth factor/scatter
RT   factor receptor.";
RL   Mol. Cell. Biol. 13:4600-4608(1993).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=8062829;
RA   Gaudino G., Follenzi A., Naldini L., Collesi C., Santoro M.,
RA   Gallo K.A., Godowski P.J., Comoglio P.M.;
RT   "RON is a heterodimeric tyrosine kinase receptor activated by the HGF
RT   homologue MSP.";
RL   EMBO J. 13:3524-3532(1994).
RN   [7]
RP   FUNCTION.
RX   PubMed=7939629; DOI=10.1126/science.7939629;
RA   Wang M.-H., Ronsin C., Gesnel M.-C., Coupey L., Skeel A.,
RA   Leonard E.J., Breatnach R.;
RT   "Identification of the ron gene product as the receptor for the human
RT   macrophage stimulating protein.";
RL   Science 266:117-119(1994).
RN   [8]
RP   FUNCTION IN WOUND HEALING RESPONSE.
RX   PubMed=9764835; DOI=10.1046/j.1523-1747.1998.00332.x;
RA   Nanney L.B., Skeel A., Luan J., Polis S., Richmond A., Wang M.H.,
RA   Leonard E.J.;
RT   "Proteolytic cleavage and activation of pro-macrophage-stimulating
RT   protein and upregulation of its receptor in tissue injury.";
RL   J. Invest. Dermatol. 111:573-581(1998).
RN   [9]
RP   INTERACTION WITH ITGB1.
RX   PubMed=10222149; DOI=10.1006/excr.1999.4429;
RA   Danilkovitch A., Skeel A., Leonard E.J.;
RT   "Macrophage stimulating protein-induced epithelial cell adhesion is
RT   mediated by a PI3-K-dependent, but FAK-independent mechanism.";
RL   Exp. Cell Res. 248:575-582(1999).
RN   [10]
RP   INTERACTION WITH MST1.
RX   PubMed=10514476; DOI=10.1074/jbc.274.42.29937;
RA   Danilkovitch A., Miller M., Leonard E.J.;
RT   "Interaction of macrophage-stimulating protein with its receptor.
RT   Residues critical for beta chain binding and evidence for independent
RT   alpha chain binding.";
RL   J. Biol. Chem. 274:29937-29943(1999).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=12472665; DOI=10.1046/j.1365-3083.2002.01177.x;
RA   Wang M.H., Zhou Y.Q., Chen Y.Q.;
RT   "Macrophage-stimulating protein and RON receptor tyrosine kinase:
RT   potential regulators of macrophage inflammatory activities.";
RL   Scand. J. Immunol. 56:545-553(2002).
RN   [12]
RP   UBIQUITINATION.
RX   PubMed=12802274; DOI=10.1038/sj.onc.1206585;
RA   Penengo L., Rubin C., Yarden Y., Gaudino G.;
RT   "c-Cbl is a critical modulator of the Ron tyrosine kinase receptor.";
RL   Oncogene 22:3669-3679(2003).
RN   [13]
RP   INTERACTION WITH HYAL2.
RX   PubMed=12676986; DOI=10.1073/pnas.0837136100;
RA   Danilkovitch-Miagkova A., Duh F.-M., Kuzmin I., Angeloni D.,
RA   Liu S.-L., Miller A.D., Lerman M.I.;
RT   "Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and
RT   mediates transformation of epithelial cells by jaagsiekte sheep
RT   retrovirus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:4580-4585(2003).
RN   [14]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=15184888; DOI=10.1038/sj.onc.1207650;
RA   Conrotto P., Corso S., Gamberini S., Comoglio P.M., Giordano S.;
RT   "Interplay between scatter factor receptors and B plexins controls
RT   invasive growth.";
RL   Oncogene 23:5131-5137(2004).
RN   [15]
RP   PHOSPHORYLATION AT TYR-1238; TYR-1239; TYR-1353 AND TYR-1360, AND
RP   ENZYME REGULATION.
RX   PubMed=15632155; DOI=10.1074/jbc.M412623200;
RA   Yokoyama N., Ischenko I., Hayman M.J., Miller W.T.;
RT   "The C terminus of RON tyrosine kinase plays an autoinhibitory role.";
RL   J. Biol. Chem. 280:8893-8900(2005).
RN   [16]
RP   FUNCTION.
RX   PubMed=18836480; DOI=10.1038/onc.2008.383;
RA   Feres K.J., Ischenko I., Hayman M.J.;
RT   "The RON receptor tyrosine kinase promotes MSP-independent cell
RT   spreading and survival in breast epithelial cells.";
RL   Oncogene 28:279-288(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   INTERACTION WITH GAB1 AND GRB2.
RX   PubMed=21784853; DOI=10.1074/jbc.M111.239384;
RA   Chaudhuri A., Xie M.H., Yang B., Mahapatra K., Liu J., Marsters S.,
RA   Bodepudi S., Ashkenazi A.;
RT   "Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal
RT   transduction by the related receptor tyrosine kinases RON and MET.";
RL   J. Biol. Chem. 286:32762-32774(2011).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.24 ANGSTROMS) OF 1060-1357 IN COMPLEX WITH
RP   AMP-PNP AND MAGNESIUM, ACTIVE SITE, AND PHOSPHORYLATION AT TYR-1238.
RX   PubMed=20726546; DOI=10.1021/bi100409w;
RA   Wang J., Steinbacher S., Augustin M., Schreiner P., Epstein D.,
RA   Mulvihill M.J., Crew A.P.;
RT   "The crystal structure of a constitutively active mutant RON kinase
RT   suggests an intramolecular autophosphorylation hypothesis.";
RL   Biochemistry 49:7972-7974(2010).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 42-568, GLYCOSYLATION AT
RP   ASN-488, AND DISULFIDE BONDS.
RX   PubMed=22848655; DOI=10.1371/journal.pone.0041912;
RA   Chao K.L., Tsai I.W., Chen C., Herzberg O.;
RT   "Crystal structure of the Sema-PSI extracellular domain of human RON
RT   receptor tyrosine kinase.";
RL   PLoS ONE 7:E41912-E41912(2012).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-75; THR-95; CYS-185; GLN-322;
RP   ASP-356; LEU-434; ASP-465; CYS-504; ARG-523; PRO-613; MET-900;
RP   GLY-1304; GLY-1335 AND CYS-1360.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [22]
RP   VARIANTS NPCA3 HIS-306; THR-327; GLY-670 AND THR-973, AND INVOLVEMENT
RP   IN NPCA3.
RX   PubMed=26951679; DOI=10.1073/pnas.1523436113;
RA   Dai W., Zheng H., Cheung A.K., Tang C.S., Ko J.M., Wong B.W.,
RA   Leong M.M., Sham P.C., Cheung F., Kwong D.L., Ngan R.K., Ng W.T.,
RA   Yau C.C., Pan J., Peng X., Tung S., Zhang Z., Ji M., Chiang A.K.,
RA   Lee A.W., Lee V.H., Lam K.O., Au K.H., Cheng H.C., Yiu H.H.,
RA   Lung M.L.;
RT   "Whole-exome sequencing identifies MST1R as a genetic susceptibility
RT   gene in nasopharyngeal carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:3317-3322(2016).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from
CC       the extracellular matrix into the cytoplasm by binding to MST1
CC       ligand. Regulates many physiological processes including cell
CC       survival, migration and differentiation. Ligand binding at the
CC       cell surface induces autophosphorylation of RON on its
CC       intracellular domain that provides docking sites for downstream
CC       signaling molecules. Following activation by ligand, interacts
CC       with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1.
CC       Recruitment of these downstream effectors by RON leads to the
CC       activation of several signaling cascades including the RAS-ERK,
CC       PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound
CC       healing response by promoting epithelial cell migration,
CC       proliferation as well as survival at the wound site. Plays also a
CC       role in the innate immune response by regulating the migration and
CC       phagocytic activity of macrophages. Alternatively, RON can also
CC       promote signals such as cell migration and proliferation in
CC       response to growth factors other than MST1 ligand.
CC       {ECO:0000269|PubMed:18836480, ECO:0000269|PubMed:7939629,
CC       ECO:0000269|PubMed:9764835}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: In its inactive state, the C-terminal tail
CC       interacts with the catalytic domain and inhibits the kinase
CC       activity. Upon ligand binding, the C-terminal tail is displaced
CC       and becomes phosphorylated, thus increasing the kinase activity.
CC       {ECO:0000269|PubMed:15632155}.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain which are
CC       disulfide linked. Binds PLXNB1. Associates with and is negatively
CC       regulated by HYAL2. Interacts when phosphorylated with downstream
CC       effectors including PIK3R1, PCLG1, GRB2 and GAB1. Interacts with
CC       integrin beta1/ITGB1 in a ligand-independent fashion.
CC       {ECO:0000269|PubMed:10222149, ECO:0000269|PubMed:10514476,
CC       ECO:0000269|PubMed:12676986, ECO:0000269|PubMed:15184888,
CC       ECO:0000269|PubMed:20726546, ECO:0000269|PubMed:21784853,
CC       ECO:0000269|PubMed:7687741}.
CC   -!- INTERACTION:
CC       P26927:MST1; NbExp=5; IntAct=EBI-2637518, EBI-6929133;
CC       O43157:PLXNB1; NbExp=3; IntAct=EBI-2637518, EBI-1111488;
CC       O15031:PLXNB2; NbExp=2; IntAct=EBI-2637518, EBI-722004;
CC       Q9ULL4:PLXNB3; NbExp=2; IntAct=EBI-2637518, EBI-311073;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=RON;
CC         IsoId=Q04912-1; Sequence=Displayed;
CC       Name=Delta-RON; Synonyms=sf-RON;
CC         IsoId=Q04912-2; Sequence=VSP_005007;
CC         Note=Lacks part of the extracellular domain, oligomerizes and is
CC         constitutively activated. Expressed at higher level in cancer
CC         cells. {ECO:0000303|PubMed:26951679};
CC       Name=RON-1;
CC         IsoId=Q04912-3; Sequence=VSP_038920, VSP_038921;
CC       Name=RON-2;
CC         IsoId=Q04912-4; Sequence=VSP_038919, VSP_038922, VSP_038923;
CC       Name=RON-3;
CC         IsoId=Q04912-5; Sequence=VSP_038924, VSP_038925;
CC       Name=RON-4;
CC         IsoId=Q04912-6; Sequence=VSP_038922, VSP_038923;
CC   -!- TISSUE SPECIFICITY: Expressed in colon, skin, lung and bone
CC       marrow. {ECO:0000269|PubMed:8062829}.
CC   -!- PTM: Proteolytic processing yields the two subunits.
CC   -!- PTM: Autophosphorylated in response to ligand binding on Tyr-1238
CC       and Tyr-1239 in the kinase domain leading to further
CC       phosphorylation of Tyr-1353 and Tyr-1360 in the C-terminal
CC       multifunctional docking site. {ECO:0000269|PubMed:15632155,
CC       ECO:0000269|PubMed:20726546}.
CC   -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor
CC       stability and activity through proteasomal degradation.
CC       {ECO:0000269|PubMed:12802274}.
CC   -!- DISEASE: Nasopharyngeal carcinoma, 3 (NPCA3) [MIM:617075]: A form
CC       of nasopharyngeal carcinoma, a malignant neoplasm that originates
CC       in the nasopharyngeal epithelium and includes 4 subtypes:
CC       keratinizing squamous cell, non-keratinizing, basaloid squamous
CC       cell, and papillary adenocarcinoma. {ECO:0000269|PubMed:26951679}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RONID287.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X70040; CAA49634.1; -; mRNA.
DR   EMBL; EU826582; ACF47618.1; -; mRNA.
DR   EMBL; EU826583; ACF47619.1; -; mRNA.
DR   EMBL; EU826584; ACF47620.1; -; mRNA.
DR   EMBL; EU826585; ACF47621.1; -; mRNA.
DR   EMBL; AC105935; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2807.1; -. [Q04912-1]
DR   CCDS; CCDS58833.1; -. [Q04912-2]
DR   PIR; I38185; I38185.
DR   RefSeq; NP_001231866.1; NM_001244937.2.
DR   RefSeq; NP_002438.2; NM_002447.3.
DR   UniGene; Hs.517973; -.
DR   PDB; 3PLS; X-ray; 2.24 A; A=1060-1357.
DR   PDB; 4FWW; X-ray; 1.85 A; A=42-568.
DR   PDB; 4QT8; X-ray; 3.00 A; A/B=25-683.
DR   PDBsum; 3PLS; -.
DR   PDBsum; 4FWW; -.
DR   PDBsum; 4QT8; -.
DR   ProteinModelPortal; Q04912; -.
DR   SMR; Q04912; -.
DR   BioGrid; 110592; 23.
DR   DIP; DIP-6029N; -.
DR   IntAct; Q04912; 15.
DR   MINT; MINT-6539690; -.
DR   STRING; 9606.ENSP00000296474; -.
DR   BindingDB; Q04912; -.
DR   ChEMBL; CHEMBL2689; -.
DR   GuidetoPHARMACOLOGY; 1816; -.
DR   iPTMnet; Q04912; -.
DR   PhosphoSitePlus; Q04912; -.
DR   BioMuta; MST1R; -.
DR   DMDM; 294862462; -.
DR   MaxQB; Q04912; -.
DR   PaxDb; Q04912; -.
DR   PeptideAtlas; Q04912; -.
DR   PRIDE; Q04912; -.
DR   DNASU; 4486; -.
DR   Ensembl; ENST00000296474; ENSP00000296474; ENSG00000164078.
DR   Ensembl; ENST00000344206; ENSP00000341325; ENSG00000164078.
DR   GeneID; 4486; -.
DR   KEGG; hsa:4486; -.
DR   UCSC; uc003cxy.5; human. [Q04912-1]
DR   CTD; 4486; -.
DR   DisGeNET; 4486; -.
DR   GeneCards; MST1R; -.
DR   HGNC; HGNC:7381; MST1R.
DR   HPA; CAB008972; -.
DR   HPA; HPA007657; -.
DR   HPA; HPA008180; -.
DR   MIM; 255995; phenotype.
DR   MIM; 600168; gene.
DR   MIM; 617075; phenotype.
DR   neXtProt; NX_Q04912; -.
DR   PharmGKB; PA31186; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG3610; Eukaryota.
DR   eggNOG; ENOG410XRIK; LUCA.
DR   HOGENOM; HOG000220900; -.
DR   HOVERGEN; HBG104342; -.
DR   InParanoid; Q04912; -.
DR   KO; K05100; -.
DR   OrthoDB; EOG091G0751; -.
DR   PhylomeDB; Q04912; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-8852405; Signaling by MST1.
DR   SignaLink; Q04912; -.
DR   SIGNOR; Q04912; -.
DR   ChiTaRS; MST1R; human.
DR   GeneWiki; MST1R; -.
DR   GenomeRNAi; 4486; -.
DR   PRO; PR:Q04912; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000164078; -.
DR   CleanEx; HS_MST1R; -.
DR   ExpressionAtlas; Q04912; baseline and differential.
DR   Genevisible; Q04912; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0001725; C:stress fiber; IEA:Ensembl.
DR   GO; GO:0005773; C:vacuole; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005011; F:macrophage colony-stimulating factor receptor activity; TAS:ProtInc.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0048012; P:hepatocyte growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006928; P:movement of cell or subcellular component; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007338; P:single fertilization; TAS:ProtInc.
DR   Gene3D; 2.130.10.10; -; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016201; PSI.
DR   InterPro; IPR001627; Semap_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016244; Tyr_kinase_HGF/MSP_rcpt.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01403; Sema; 1.
DR   Pfam; PF01833; TIG; 3.
DR   PIRSF; PIRSF000617; TyrPK_HGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00429; IPT; 3.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00630; Sema; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF101912; SSF101912; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF81296; SSF81296; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS51004; SEMA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Immunity;
KW   Innate immunity; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25   1400       Macrophage-stimulating protein receptor.
FT                                /FTId=PRO_0000024452.
FT   CHAIN        25    304       Macrophage-stimulating protein receptor
FT                                alpha chain. {ECO:0000255}.
FT                                /FTId=PRO_0000024453.
FT   CHAIN       310   1400       Macrophage-stimulating protein receptor
FT                                beta chain. {ECO:0000255}.
FT                                /FTId=PRO_0000024454.
FT   TOPO_DOM     25    957       Extracellular. {ECO:0000255}.
FT   TRANSMEM    958    978       Helical. {ECO:0000255}.
FT   TOPO_DOM    979   1400       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       31    522       Sema. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00352}.
FT   DOMAIN      569    671       IPT/TIG 1.
FT   DOMAIN      684    767       IPT/TIG 2.
FT   DOMAIN      770    860       IPT/TIG 3.
FT   DOMAIN     1082   1345       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1088   1096       ATP.
FT   NP_BIND    1161   1164       ATP.
FT   COMPBIAS    306    309       Poly-Arg.
FT   COMPBIAS    962    968       Poly-Leu.
FT   ACT_SITE   1208   1208       Proton acceptor.
FT                                {ECO:0000305|PubMed:20726546}.
FT   BINDING    1114   1114       ATP.
FT   BINDING    1212   1212       ATP.
FT   MOD_RES    1238   1238       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:15632155,
FT                                ECO:0000305|PubMed:20726546}.
FT   MOD_RES    1239   1239       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:15632155}.
FT   MOD_RES    1353   1353       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15632155}.
FT   MOD_RES    1360   1360       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15632155}.
FT   CARBOHYD     66     66       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    419    419       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    458    458       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    488    488       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22848655}.
FT   CARBOHYD    654    654       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    720    720       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    841    841       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    897    897       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    101    104       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    107    162       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    135    143       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    174    177       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    300    367       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    385    407       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    386    422       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    527    545       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    533    567       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    536    552       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   DISULFID    548    558       {ECO:0000255|PROSITE-ProRule:PRU00352,
FT                                ECO:0000269|PubMed:22848655}.
FT   VAR_SEQ     411    516       Missing (in isoform RON-2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_038919.
FT   VAR_SEQ     475    495       ELVRSLNYLLYVSNFSLGDSG -> GPHPHSPLALGPCLHP
FT                                HFAHI (in isoform RON-1).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_038920.
FT   VAR_SEQ     496   1400       Missing (in isoform RON-1).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_038921.
FT   VAR_SEQ     628    647       PVPRKDFVEEFECELEPLGT -> YNLVPPLPFPEGGNQAA
FT                                PSP (in isoform RON-2 and isoform RON-4).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_038922.
FT   VAR_SEQ     648   1400       Missing (in isoform RON-2 and isoform
FT                                RON-4). {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_038923.
FT   VAR_SEQ     884    932       Missing (in isoform Delta-RON).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005007.
FT   VAR_SEQ     884    907       YIGLGAVADCVGINVTVGGESCQH -> VSVRDRGRDSWGS
FT                                ESRGQPTGWSS (in isoform RON-3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_038924.
FT   VAR_SEQ     908   1400       Missing (in isoform RON-3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_038925.
FT   VARIANT      75     75       R -> S (in dbSNP:rs35887539).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041768.
FT   VARIANT      95     95       P -> T (in dbSNP:rs55908300).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041769.
FT   VARIANT     185    185       R -> C (in dbSNP:rs55633379).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041770.
FT   VARIANT     306    306       R -> H (in NPCA3).
FT                                {ECO:0000269|PubMed:26951679}.
FT                                /FTId=VAR_076928.
FT   VARIANT     322    322       R -> Q (in dbSNP:rs2230593).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8386824}.
FT                                /FTId=VAR_006350.
FT   VARIANT     327    327       A -> T (in NPCA3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26951679}.
FT                                /FTId=VAR_076929.
FT   VARIANT     356    356       G -> D (in dbSNP:rs35924402).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041771.
FT   VARIANT     434    434       S -> L (in dbSNP:rs2230591).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_029238.
FT   VARIANT     440    440       N -> S (in dbSNP:rs2230592).
FT                                /FTId=VAR_029239.
FT   VARIANT     465    465       G -> D (in dbSNP:rs34564898).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041772.
FT   VARIANT     504    504       R -> C (in dbSNP:rs34350470).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041773.
FT   VARIANT     523    523       Q -> R (in dbSNP:rs2230590).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8386824}.
FT                                /FTId=VAR_041774.
FT   VARIANT     613    613       Q -> P (in dbSNP:rs35986685).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041775.
FT   VARIANT     670    670       V -> G (in NPCA3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26951679}.
FT                                /FTId=VAR_076930.
FT   VARIANT     900    900       V -> M (in dbSNP:rs56091918).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041776.
FT   VARIANT     973    973       A -> T (in NPCA3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26951679}.
FT                                /FTId=VAR_076931.
FT   VARIANT    1195   1195       S -> G (in dbSNP:rs7433231).
FT                                {ECO:0000269|PubMed:8386824}.
FT                                /FTId=VAR_061749.
FT   VARIANT    1304   1304       R -> G. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041777.
FT   VARIANT    1335   1335       R -> G (in dbSNP:rs1062633).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_024577.
FT   VARIANT    1360   1360       Y -> C (in dbSNP:rs56330223).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041778.
FT   CONFLICT    209    209       A -> G (in Ref. 1; CAA49634).
FT                                {ECO:0000305}.
FT   CONFLICT    813    813       R -> RQ (in Ref. 3; ACF47620).
FT                                {ECO:0000305}.
FT   STRAND       43     45       {ECO:0000244|PDB:4FWW}.
FT   STRAND       48     50       {ECO:0000244|PDB:4FWW}.
FT   STRAND       55     62       {ECO:0000244|PDB:4FWW}.
FT   STRAND       64     66       {ECO:0000244|PDB:4QT8}.
FT   STRAND       68     74       {ECO:0000244|PDB:4FWW}.
FT   STRAND       77     81       {ECO:0000244|PDB:4FWW}.
FT   STRAND       87     92       {ECO:0000244|PDB:4FWW}.
FT   STRAND       96     98       {ECO:0000244|PDB:4QT8}.
FT   HELIX       102    105       {ECO:0000244|PDB:4FWW}.
FT   STRAND      108    110       {ECO:0000244|PDB:4FWW}.
FT   STRAND      120    126       {ECO:0000244|PDB:4FWW}.
FT   TURN        127    130       {ECO:0000244|PDB:4FWW}.
FT   STRAND      131    138       {ECO:0000244|PDB:4FWW}.
FT   HELIX       139    141       {ECO:0000244|PDB:4FWW}.
FT   STRAND      143    151       {ECO:0000244|PDB:4FWW}.
FT   STRAND      154    157       {ECO:0000244|PDB:4FWW}.
FT   STRAND      161    163       {ECO:0000244|PDB:4QT8}.
FT   TURN        166    168       {ECO:0000244|PDB:4QT8}.
FT   STRAND      184    191       {ECO:0000244|PDB:4FWW}.
FT   STRAND      194    201       {ECO:0000244|PDB:4FWW}.
FT   HELIX       205    208       {ECO:0000244|PDB:4FWW}.
FT   STRAND      209    211       {ECO:0000244|PDB:4FWW}.
FT   STRAND      215    221       {ECO:0000244|PDB:4FWW}.
FT   STRAND      233    235       {ECO:0000244|PDB:4FWW}.
FT   HELIX       239    242       {ECO:0000244|PDB:4FWW}.
FT   STRAND      248    255       {ECO:0000244|PDB:4FWW}.
FT   STRAND      258    268       {ECO:0000244|PDB:4FWW}.
FT   STRAND      269    271       {ECO:0000244|PDB:4QT8}.
FT   STRAND      275    288       {ECO:0000244|PDB:4FWW}.
FT   HELIX       290    292       {ECO:0000244|PDB:4QT8}.
FT   STRAND      294    302       {ECO:0000244|PDB:4FWW}.
FT   STRAND      309    311       {ECO:0000244|PDB:4QT8}.
FT   STRAND      316    318       {ECO:0000244|PDB:4FWW}.
FT   STRAND      320    328       {ECO:0000244|PDB:4FWW}.
FT   HELIX       331    337       {ECO:0000244|PDB:4FWW}.
FT   STRAND      344    351       {ECO:0000244|PDB:4FWW}.
FT   STRAND      365    370       {ECO:0000244|PDB:4FWW}.
FT   HELIX       371    386       {ECO:0000244|PDB:4FWW}.
FT   STRAND      387    389       {ECO:0000244|PDB:4FWW}.
FT   TURN        399    401       {ECO:0000244|PDB:4FWW}.
FT   STRAND      407    409       {ECO:0000244|PDB:4QT8}.
FT   HELIX       422    424       {ECO:0000244|PDB:4FWW}.
FT   STRAND      433    436       {ECO:0000244|PDB:4FWW}.
FT   TURN        438    445       {ECO:0000244|PDB:4FWW}.
FT   STRAND      448    456       {ECO:0000244|PDB:4FWW}.
FT   STRAND      459    466       {ECO:0000244|PDB:4FWW}.
FT   STRAND      469    475       {ECO:0000244|PDB:4FWW}.
FT   STRAND      485    491       {ECO:0000244|PDB:4FWW}.
FT   STRAND      503    505       {ECO:0000244|PDB:4FWW}.
FT   STRAND      508    513       {ECO:0000244|PDB:4FWW}.
FT   STRAND      516    521       {ECO:0000244|PDB:4FWW}.
FT   HELIX       527    529       {ECO:0000244|PDB:4FWW}.
FT   HELIX       533    538       {ECO:0000244|PDB:4FWW}.
FT   HELIX       541    543       {ECO:0000244|PDB:4FWW}.
FT   STRAND      549    553       {ECO:0000244|PDB:4FWW}.
FT   HELIX       555    557       {ECO:0000244|PDB:4FWW}.
FT   TURN        559    561       {ECO:0000244|PDB:4FWW}.
FT   STRAND      563    567       {ECO:0000244|PDB:4QT8}.
FT   STRAND      570    575       {ECO:0000244|PDB:4QT8}.
FT   STRAND      578    580       {ECO:0000244|PDB:4QT8}.
FT   STRAND      589    593       {ECO:0000244|PDB:4QT8}.
FT   STRAND      609    615       {ECO:0000244|PDB:4QT8}.
FT   STRAND      639    641       {ECO:0000244|PDB:4QT8}.
FT   STRAND      653    659       {ECO:0000244|PDB:4QT8}.
FT   STRAND      672    682       {ECO:0000244|PDB:4QT8}.
FT   HELIX      1064   1069       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1071   1073       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1077   1079       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1080   1091       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1094   1102       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1104   1106       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1108   1116       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1122   1136       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1148   1150       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1153   1155       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1158   1161       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1169   1174       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1182   1201       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1211   1213       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1214   1216       {ECO:0000244|PDB:3PLS}.
FT   STRAND     1222   1224       {ECO:0000244|PDB:3PLS}.
FT   TURN       1232   1235       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1236   1239       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1250   1253       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1256   1259       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1266   1282       {ECO:0000244|PDB:3PLS}.
FT   TURN       1287   1290       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1293   1295       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1296   1301       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1314   1323       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1328   1330       {ECO:0000244|PDB:3PLS}.
FT   HELIX      1334   1347       {ECO:0000244|PDB:3PLS}.
SQ   SEQUENCE   1400 AA;  152271 MW;  EB5CA79ABC69A882 CRC64;
     MELLPPLPQS FLLLLLLPAK PAAGEDWQCP RTPYAASRDF DVKYVVPSFS AGGLVQAMVT
     YEGDRNESAV FVAIRNRLHV LGPDLKSVQS LATGPAGDPG CQTCAACGPG PHGPPGDTDT
     KVLVLDPALP ALVSCGSSLQ GRCFLHDLEP QGTAVHLAAP ACLFSAHHNR PDDCPDCVAS
     PLGTRVTVVE QGQASYFYVA SSLDAAVAAS FSPRSVSIRR LKADASGFAP GFVALSVLPK
     HLVSYSIEYV HSFHTGAFVY FLTVQPASVT DDPSALHTRL ARLSATEPEL GDYRELVLDC
     RFAPKRRRRG APEGGQPYPV LRVAHSAPVG AQLATELSIA EGQEVLFGVF VTGKDGGPGV
     GPNSVVCAFP IDLLDTLIDE GVERCCESPV HPGLRRGLDF FQSPSFCPNP PGLEALSPNT
     SCRHFPLLVS SSFSRVDLFN GLLGPVQVTA LYVTRLDNVT VAHMGTMDGR ILQVELVRSL
     NYLLYVSNFS LGDSGQPVQR DVSRLGDHLL FASGDQVFQV PIQGPGCRHF LTCGRCLRAW
     HFMGCGWCGN MCGQQKECPG SWQQDHCPPK LTEFHPHSGP LRGSTRLTLC GSNFYLHPSG
     LVPEGTHQVT VGQSPCRPLP KDSSKLRPVP RKDFVEEFEC ELEPLGTQAV GPTNVSLTVT
     NMPPGKHFRV DGTSVLRGFS FMEPVLIAVQ PLFGPRAGGT CLTLEGQSLS VGTSRAVLVN
     GTECLLARVS EGQLLCATPP GATVASVPLS LQVGGAQVPG SWTFQYREDP VVLSISPNCG
     YINSHITICG QHLTSAWHLV LSFHDGLRAV ESRCERQLPE QQLCRLPEYV VRDPQGWVAG
     NLSARGDGAA GFTLPGFRFL PPPHPPSANL VPLKPEEHAI KFEYIGLGAV ADCVGINVTV
     GGESCQHEFR GDMVVCPLPP SLQLGQDGAP LQVCVDGECH ILGRVVRPGP DGVPQSTLLG
     ILLPLLLLVA ALATALVFSY WWRRKQLVLP PNLNDLASLD QTAGATPLPI LYSGSDYRSG
     LALPAIDGLD STTCVHGASF SDSEDESCVP LLRKESIQLR DLDSALLAEV KDVLIPHERV
     VTHSDRVIGK GHFGVVYHGE YIDQAQNRIQ CAIKSLSRIT EMQQVEAFLR EGLLMRGLNH
     PNVLALIGIM LPPEGLPHVL LPYMCHGDLL QFIRSPQRNP TVKDLISFGL QVARSMEYLA
     EQKFVHRDLA ARNCMLDESF TVKVADFGLA RDILDREYYS VQQHRHARLP VKWMALESLQ
     TYRFTTKSDV WSFGVLLWEL LTRGAPPYRH IDPFDLTHFL AQGRRLPQPE YCPDSLYQVM
     QQCWEADPAV RPTFRVLVGE VEQIVSALLG DHYVQLPATY MNLGPSTSHE MNVRPEQPQF
     SPMPGNVRRP RPLSEPPRPT
//
